International
The Morning Science

What science found today

‹
 

Research

expert reaction to abstract about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma

Science Media Centre ·

The Brief

  • An abstract presented at EORTC-NCI-AACR 2026 reports on daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma.
  • Shivan Sivakumar, Professor of Translational Oncology at the University of Birmingham, described the results as very encouraging.

Why it matters

The source covers early expert reaction to a treatment combination tested in metastatic pancreatic adenocarcinoma, a disease where the expert called the results encouraging. Only the abstract and a brief expert reaction are available, so the full data are not yet known.

Who’s affected

  • oncologists and pancreatic cancer researchers
  • patients with metastatic pancreatic adenocarcinoma and their clinicians

Scientist reacts to abstract presented at EORTC-NCI-AACR 2026* about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma. Prof Shivan Sivakumar, Professor of Translational Oncology, University of Birmingham, said: “These are very encouraging results in a disease where…

How do you feel about this?

0 Comments

    expert reaction to abstract about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma – The Morning Science